1. Home
  2. ESEA vs ARVN Comparison

ESEA vs ARVN Comparison

Compare ESEA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Euroseas Ltd. (Marshall Islands)

ESEA

Euroseas Ltd. (Marshall Islands)

SELL

Current Price

$65.17

Market Cap

557.0M

ML Signal

SELL

Logo Arvinas Inc.

ARVN

Arvinas Inc.

SELL

Current Price

$6.71

Market Cap

600.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ESEA
ARVN
Founded
2005
2015
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
557.0M
600.2M
IPO Year
2005
2018

Fundamental Metrics

Financial Performance
Metric
ESEA
ARVN
Price
$65.17
$6.71
Analyst Decision
Strong Buy
Buy
Analyst Count
4
15
Target Price
★ $91.75
$14.00
AVG Volume (30 Days)
20.2K
★ 879.9K
Earning Date
11-17-2026
11-03-2026
Dividend Yield
★ 4.90%
N/A
EPS Growth
N/A
★ 58.84
EPS
N/A
★ 0.88
Revenue
N/A
★ $262,600,000.00
Revenue This Year
N/A
$5.67
Revenue Next Year
$3.94
N/A
P/E Ratio
★ $3.39
$7.69
Revenue Growth
★ N/A
N/A
52 Week Low
$51.00
$6.33
52 Week High
$79.67
$14.20

Technical Indicators

Market Signals
Indicator
ESEA
ARVN
Relative Strength Index (RSI) 41.04 41.53
Support Level $63.29 $6.54
Resistance Level $72.56 $7.85
Average True Range (ATR) 2.13 0.46
MACD 0.30 -0.02
Stochastic Oscillator 27.21 25.88

Price Performance

Historical Comparison
ESEA
ARVN

About ESEA Euroseas Ltd. (Marshall Islands)

Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: